Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04776239 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)
A Phase 1 study, sponsored by Joshua M Hare.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04776239 is a Phase 1 study that has completed, run by Joshua M Hare. The registered enrollment target is 26 participants.
The verdict
NCT04776239, a Phase 1 study, has completed, sponsored by Joshua M Hare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.
Interventions
- OTHER Placebo
- DRUG 100 million Allogeneic Mesenchymal Human Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04776239
The ClinicalTrials.gov registry entry for NCT04776239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joshua M Hare, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04776239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04776239 about?
NCT04776239 is a clinical study titled "Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)". The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.
What is the current status of trial NCT04776239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2021-08-16. Estimated completion is 2025-08-26.
What interventions are being tested in trial NCT04776239?
The interventions under investigation include: Placebo (OTHER), 100 million Allogeneic Mesenchymal Human Stem Cells (DRUG).
Who is sponsoring clinical trial NCT04776239?
This trial is sponsored by Joshua M Hare, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.